Log in
CVE:GAP

14033 (GAP.V) Stock Forecast, Price & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PharmaGap Inc. (PharmaGap) is a development-stage company. The Company is principally engaged in drug development and out-licensing of drug compounds. The Company is focused on the development of novel drugs for treatment of cancer and other human disease conditions. PharmaGap's lead drug compound, GAP-107B8, is in the pre-clinical testing stage and has shown in vitro and in vivo efficacy in selected cancer types. During the year ended December 31, 2011, the Company commenced specific programs to further elucidate information regarding the pharmacokinetics and toxicity profiles of GAP-107B8. A program to develop liposomal delivery formulations of GAP-107B8 in order to optimize the delivery and safety of the drug compound was completed during 2011. The Company is developing GAP-107B8 for first clinical trials in ovarian cancer, using the intra-peritoneal route of administration.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.44 out of 5 stars


Industry, Sector and Symbol

Stock Exchange CVE
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolCVE:GAP
Previous Symbol
CUSIPN/A
CIKN/A
WebN/A
Phone+1-613-2873118
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive GAP News and Ratings via Email

Sign-up to receive the latest news and ratings for GAP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











14033 (GAP.V) (CVE:GAP) Frequently Asked Questions

What stocks does MarketBeat like better than 14033 (GAP.V)?

Wall Street analysts have given 14033 (GAP.V) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 14033 (GAP.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is 14033 (GAP.V)'s stock symbol?

14033 (GAP.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GAP."

How do I buy shares of 14033 (GAP.V)?

Shares of GAP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How can I contact 14033 (GAP.V)?

14033 (GAP.V)'s mailing address is 1000 Innovation Drive, Suite 400, OTTAWA, ON K2K 2K7, Canada. The company can be reached via phone at +1-613-2873118.

This page was last updated on 11/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.